CCR5 Receptor Antagonists
"CCR5 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds and drugs that inhibit or block the activity of CCR5 RECEPTORS.
| Descriptor ID |
D065100
|
| MeSH Number(s) |
D27.505.519.275 D27.505.954.122.388.077.088.104
|
| Concept/Terms |
CCR5 Receptor Antagonists- CCR5 Receptor Antagonists
- Antagonists, CCR5 Receptor
- Receptor Antagonists, CCR5
- CC Chemokine Receptor 5 Blockers
- Chemokine Co-receptor 5 Antagonists
- Chemokine Co receptor 5 Antagonists
- HIV-1 Fusion Coreceptor Antagonists
- HIV 1 Fusion Coreceptor Antagonists
- CC Chemokine Receptor 5 Antagonists
- CCR5 Receptor Blockers
- Blockers, CCR5 Receptor
- Receptor Blockers, CCR5
|
Below are MeSH descriptors whose meaning is more general than "CCR5 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "CCR5 Receptor Antagonists".
This graph shows the total number of publications written about "CCR5 Receptor Antagonists" by people in this website by year, and whether "CCR5 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 8 | 0 | 8 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CCR5 Receptor Antagonists" by people in Profiles.
-
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. 2021 Feb; 103:25-32.
-
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications. Cardiorenal Med. 2020; 10(5):277-287.
-
Impact of prolonged maraviroc treatment on non-AIDS-related comorbidities in HIV-positive patients: a retrospective cohort study. J Antimicrob Chemother. 2019 09 01; 74(9):2723-2731.
-
Unexpected drug emerges for stroke recovery. Science. 2019 02 22; 363(6429):805.
-
Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists. J Med Chem. 2018 11 08; 61(21):9621-9636.
-
Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. Infez Med. 2018 Jun 01; 26(2):160-163.
-
Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. Pediatr Infect Dis J. 2018 05; 37(5):459-465.
-
A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. Eur J Pharm Sci. 2018 May 30; 117:313-320.
-
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018 04; 67(4):1270-1283.
-
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018 05; 67(5):1754-1767.